New cancer drug trial seeks to turn Patient's own immune cells against tumors
Disease control
Recruiting now
This early-stage trial is testing a new drug called RPTR-1-201, which is designed to guide a patient's own immune cells to attack advanced solid tumors. It will enroll about 150 adults to first find a safe dose and then see if the drug can shrink tumors, either alone or combined …
Phase: PHASE1, PHASE2 • Sponsor: Repertoire Immune Medicines • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC